Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Morphea Clinical Trial

Official title:

Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03351114
• Other study ID #: Pro00086947
• Status: Completed
• Phase: Phase 2
• Start date: September 1, 2018
• Est. completion date: March 10, 2020

Study information

• Verified date: March 2021
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study to determine the safety and clinical efficacy of crisaborole 2% ointment in the treatment of morphea.

Description:

A Phase 2, pilot, proof-of-concept, open label, single arm prospective study to assess the safety, tolerability and efficacy of using crisaborole 2% ointment for adult morphea. Patients identified by their physician, nurse, or other member of their clinical care team as meeting criteria for the study will be asked to apply crisaborole 2% ointment, twice daily, on affected plaques for 12 weeks. A 4 mm skin punch biopsy will be performed at baseline and at 12 weeks, on the same affected plaque. Dermal thickness will be measured and compared before and at the end of treatment. Patients will have a clinical assessment at baseline and at weeks 4, 8 and 12. After week 12, patients who need further treatment will undergo standard of care treatment as determined by their primary dermatologist. Physician and patient reported assessment and skin imaging will be performed at baseline, week 4, 8 and 12, and at week 20. Photography will also be performed at baseline and week 12. An optional post treatment follow-up will be performed at week 20.

Medication will be provided free of charge by Pfizer, as part of the grant that is funding this study. These will be dispensed by the study group at baseline and during the subsequent clinic visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 8
• Est. completion date: March 10, 2020
• Est. primary completion date: March 10, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. >= 18 years of age

2. Clinical diagnosis of morphea.

3. <20% Total body surface area involvement.

4. Does not require systemic immunosuppressive therapy for morphea.

5. No immunosuppressive systemic therapy 1 month prior to starting the study (methotrexate, mycophenolate mofetil, azathioprine, cyclosporine, cyclophosphamide, prednisone >=10 mg PO daily).

6. No immunomodulating topical therapy (topical steroids or topical calcineurin inhibitor), and no topical vitamin D analogue, 2 weeks prior to starting study.

7. No allergy to crisaborole or vehicle.

8. No known renal disease

9. Able to give informed consent.

Exclusion Criteria:Subjects fulfilling any of the following criteria are not eligible for inclusion in this study.

1. Clinical diagnosis of depression or history of suicidal ideation.

2. Pregnant or breastfeeding women, with pregnant women being defined as the state of a female after conception until the termination of gestation, confirmed by a positive urine human chorionic gonadotropin (hCG) laboratory test. Women with a positive urine hCG at any time during the study will be withdrawn from the study.

Related Conditions & MeSH terms

• Morphea
• Scleroderma, Localized

Intervention

Drug:
• Crisaborole
Apply Crisaborole 2% ointment to affected skin twice per day.

Locations

Country	Name	City	State
United States	Duke University	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants Who Had a Reduction in Dermal Thickness of Sentinel Plaque	Change in dermal thickness on skin biopsy. A sentinel plaque will be selected at baseline. A 4 mm skin punch biopsy will be performed at baseline and at 12 weeks, on the same affected plaque.	Baseline, 12 weeks
Secondary	Percentage of Reduction in DIET Score of Sentinel Plaque	The DIET (Dyspigmentation, Induration, Erythema, and Telangiectasias) score is a physician-assessed, previously validated score. Range is 0-12, and a higher score denotes increased activity or severity.	Baseline and 12 weeks
Secondary	Percentage of Reduction in LoSCAT Score	LoSCAT (Localized Scleroderma Cutaneous Assessment Tool ) score is a physician-assessed, previously validated score. It has 2 components, the LoSSI (localized scleroderma skin severity index, range 0-162), which measures disease activity, and LoSDI (localized scleroderma damage index, range 0-216). The higher the number, the higher the disease activity and damage, respectively.	Baseline,12 weeks
Secondary	Percentage of Reduction in Skindex-29 Score	Skindex-29 is a health-related quality of life score; minimum score 30, maximum 150. Lower score indicates a better quality of life.	Baseline and 12 weeks
Secondary	Change in Dermal Thickness of Sentinel Plaque by Ultrasonography	B-Mode ultrasonographic imaging will be utilized to measure dermal thickness of the sentinel plaque	Baseline, 4, 8 and 12 weeks, optional at 20 weeks